{"organizations": [], "uuid": "568a1452fc86cc370f6be00742f958a06eca621e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-xenon-pharma-teva-pharma-terminate/brief-xenon-pharma-teva-pharma-terminate-development-license-agreement-idUSASB0C99D", "country": "US", "domain_rank": 408, "title": "BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T05:40:00.000+02:00", "replies_count": 0, "uuid": "568a1452fc86cc370f6be00742f958a06eca621e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-xenon-pharma-teva-pharma-terminate/brief-xenon-pharma-teva-pharma-terminate-development-license-agreement-idUSASB0C99D", "ord_in_thread": 0, "title": "BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-xenon pharma", "sentiment": "negative"}, {"name": "teva pharma terminate development", "sentiment": "negative"}, {"name": "reuters) - xenon pharmaceuticals inc", "sentiment": "neutral"}, {"name": "dec", "sentiment": "none"}, {"name": "teva pharmaceuticals international gmbh", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* XENON PHARMA - CO, TEVA PHARMACEUTICALS INTERNATIONAL GMBH, TEVA CANADA, ENTERED DEAL TO MUTUALLY TERMINATE DEC 7, 2012 DEVELOPMENT & LICENSE AGREEMENT\n* XENON PHARMA - AS PER TERMINATION AGREEMENT, TEVA AGREED TO TRANSFER AND ASSIGN 1 MILLION SHARES OF CO HELD BY TEVA CANADA LTD TO CO FOR CANCELLATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T05:40:00.000+02:00", "crawled": "2018-03-08T17:01:51.000+02:00", "highlightTitle": ""}